Objectives We aimed to evaluate the impact of first-to-second progression free survival (PFS1/PFS2) ratio on overall survival (OS) in patients with ovarian cancer.
Methods A retrospective cohort study of all patients with ovarian carcinoma treated in one university-affiliated medical center (2000–7/2017). We included patients who had at-least a second recurrence. We included patients who were initially platinum sensitive, therefore patients with first progression-free survival (PFS) less than 12 months were excluded. Study groups included patients with PFS1/PFS2 <1.0 and patients with PFS1/PFS2 ≥1.0. Demographics and treatment outcomes were compared between groups. The primary outcome was OS. In addition, we assessed the linear correlation between first and second PFS.
P value <0.05 was considered significant.
Results Overall, 65 patients met inclusion criteria. In this cohort, the mean of first PFS was 64.6±54.3 months, and the mean for the second PFS was 20.8±32.4. Overall, 13 (20%) had PFS1/PFS2 <1.0 and 52 (80%) had PFS1/PFS2 ≥1.0. Patients in the PFS1/PFS2 <1.0 group were younger, although not reaching statistical significance (median age 48 vs. 59 years, p=0.05). There were no significant difference in stage of disease or histology. There were no difference in rates of neoadjuvant chemotherapy between groups (15.4% vs 34.6%, p=0.31). In a Kaplan-Meier analysis, there were no difference between groups in OS (figure 1). Using Pearson’s Correlation coefficient, longer first PFS was associated with longer second PFS (r=0.3).
Conclusions In patients with ovarian cancer, longer first PFS seems to be associated with longer second PFS. However, first-to-second PFS ratio does not predict OS.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.